Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy

Dae Ho Cho, Tai Gyu Kim, Wangjae Lee, Young Il Hwang, Hyun Il Cho, Hoon Han, Ohchan Kwon, Daejin Kim, Hyunjeong Park, Dong Houh

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Interleukin-18 has been described recently as a cytokine secreted primarily by Kupffer cells. Furthermore, it has been shown that it has significant anti-tumor effects, which are mediated by T cells and natural killer cells, in a manner similar to interleukin-12. Here, we report the evaluation of the effects of the systemic administration of interleukin-18 in combination with B7-1 (CD80) expressed on tumor cells [interleukin-18 + B7-1] on the growth of murine B16 melanoma in vivo. After the subcutaneous inoculation of B16 melanoma, B16 tumors grew progressively in immunocompetent syngeneic C57BL/6 mice. Mice treated with either interleukin-18 or immunized with B7-1-transduced B16 did not demonstrate significant anti-tumor effect. The combination of the two treatments, however, resulted in dramatic suppression of melanoma formation, tumor growth, and a significant improvement in survival. Inhibitory effects of [interleukin-18 + B7-1] on lung metastasis in mice were also detected. Additionally, mice treated with [interleukin-18 + B7-1] showed an increase of natural killer cytotoxicity and interferon-γ production in vivo. Unlike [interleukin-18 + B7-1], [interleukin-12 + B7-1] did not have a strong antitumor effect against B16 melanoma. Histologic characterization after the [interleukin-18 + B7-1] treatment confirmed the infiltration of natural killer cells into the tumor, suggesting that natural killer cells may be involved in the [interleukin-18 + B7-1]-induced anti-tumor effect. This finding was confirmed by showing that depletion of NK1.1+ cells before immunization inhibits the [interleukin-18 + B7-1]-induced anti-tumor effect. Depletion of CD3+ cells in vivo also decreased the anti-tumor effect of [interleukin-18 + B7-1], suggesting the importance of CD3+ T cells. Collectively, combination with interleukin-18 and B7-1 expression has synergistic anti-tumor effects against B16 murine melanoma.

Original languageEnglish
Pages (from-to)928-934
Number of pages7
JournalJournal of Investigative Dermatology
Volume114
Issue number5
DOIs
Publication statusPublished - 2000 Jan 1

Fingerprint

CD80 Antigens
Interleukin-18
Immunotherapy
Tumors
Melanoma
Neoplasms
Experimental Melanomas
Interleukin-12
Natural Killer Cells
T-cells
Immunization
T-Lymphocytes
Kupffer Cells
Population Growth
Cytotoxicity
Growth
Inbred C57BL Mouse
Infiltration
Interferons

Keywords

  • Anti-tumor effect
  • B7-1
  • Immunotherapy
  • Interleukin-18
  • Melanoma

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy. / Cho, Dae Ho; Kim, Tai Gyu; Lee, Wangjae; Hwang, Young Il; Cho, Hyun Il; Han, Hoon; Kwon, Ohchan; Kim, Daejin; Park, Hyunjeong; Houh, Dong.

In: Journal of Investigative Dermatology, Vol. 114, No. 5, 01.01.2000, p. 928-934.

Research output: Contribution to journalArticle

Cho, Dae Ho ; Kim, Tai Gyu ; Lee, Wangjae ; Hwang, Young Il ; Cho, Hyun Il ; Han, Hoon ; Kwon, Ohchan ; Kim, Daejin ; Park, Hyunjeong ; Houh, Dong. / Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy. In: Journal of Investigative Dermatology. 2000 ; Vol. 114, No. 5. pp. 928-934.
@article{7a26ff51e3404b6c9b046ec5b6534720,
title = "Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy",
abstract = "Interleukin-18 has been described recently as a cytokine secreted primarily by Kupffer cells. Furthermore, it has been shown that it has significant anti-tumor effects, which are mediated by T cells and natural killer cells, in a manner similar to interleukin-12. Here, we report the evaluation of the effects of the systemic administration of interleukin-18 in combination with B7-1 (CD80) expressed on tumor cells [interleukin-18 + B7-1] on the growth of murine B16 melanoma in vivo. After the subcutaneous inoculation of B16 melanoma, B16 tumors grew progressively in immunocompetent syngeneic C57BL/6 mice. Mice treated with either interleukin-18 or immunized with B7-1-transduced B16 did not demonstrate significant anti-tumor effect. The combination of the two treatments, however, resulted in dramatic suppression of melanoma formation, tumor growth, and a significant improvement in survival. Inhibitory effects of [interleukin-18 + B7-1] on lung metastasis in mice were also detected. Additionally, mice treated with [interleukin-18 + B7-1] showed an increase of natural killer cytotoxicity and interferon-γ production in vivo. Unlike [interleukin-18 + B7-1], [interleukin-12 + B7-1] did not have a strong antitumor effect against B16 melanoma. Histologic characterization after the [interleukin-18 + B7-1] treatment confirmed the infiltration of natural killer cells into the tumor, suggesting that natural killer cells may be involved in the [interleukin-18 + B7-1]-induced anti-tumor effect. This finding was confirmed by showing that depletion of NK1.1+ cells before immunization inhibits the [interleukin-18 + B7-1]-induced anti-tumor effect. Depletion of CD3+ cells in vivo also decreased the anti-tumor effect of [interleukin-18 + B7-1], suggesting the importance of CD3+ T cells. Collectively, combination with interleukin-18 and B7-1 expression has synergistic anti-tumor effects against B16 murine melanoma.",
keywords = "Anti-tumor effect, B7-1, Immunotherapy, Interleukin-18, Melanoma",
author = "Cho, {Dae Ho} and Kim, {Tai Gyu} and Wangjae Lee and Hwang, {Young Il} and Cho, {Hyun Il} and Hoon Han and Ohchan Kwon and Daejin Kim and Hyunjeong Park and Dong Houh",
year = "2000",
month = "1",
day = "1",
doi = "10.1038/sj.jid.5600685",
language = "English",
volume = "114",
pages = "928--934",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy

AU - Cho, Dae Ho

AU - Kim, Tai Gyu

AU - Lee, Wangjae

AU - Hwang, Young Il

AU - Cho, Hyun Il

AU - Han, Hoon

AU - Kwon, Ohchan

AU - Kim, Daejin

AU - Park, Hyunjeong

AU - Houh, Dong

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Interleukin-18 has been described recently as a cytokine secreted primarily by Kupffer cells. Furthermore, it has been shown that it has significant anti-tumor effects, which are mediated by T cells and natural killer cells, in a manner similar to interleukin-12. Here, we report the evaluation of the effects of the systemic administration of interleukin-18 in combination with B7-1 (CD80) expressed on tumor cells [interleukin-18 + B7-1] on the growth of murine B16 melanoma in vivo. After the subcutaneous inoculation of B16 melanoma, B16 tumors grew progressively in immunocompetent syngeneic C57BL/6 mice. Mice treated with either interleukin-18 or immunized with B7-1-transduced B16 did not demonstrate significant anti-tumor effect. The combination of the two treatments, however, resulted in dramatic suppression of melanoma formation, tumor growth, and a significant improvement in survival. Inhibitory effects of [interleukin-18 + B7-1] on lung metastasis in mice were also detected. Additionally, mice treated with [interleukin-18 + B7-1] showed an increase of natural killer cytotoxicity and interferon-γ production in vivo. Unlike [interleukin-18 + B7-1], [interleukin-12 + B7-1] did not have a strong antitumor effect against B16 melanoma. Histologic characterization after the [interleukin-18 + B7-1] treatment confirmed the infiltration of natural killer cells into the tumor, suggesting that natural killer cells may be involved in the [interleukin-18 + B7-1]-induced anti-tumor effect. This finding was confirmed by showing that depletion of NK1.1+ cells before immunization inhibits the [interleukin-18 + B7-1]-induced anti-tumor effect. Depletion of CD3+ cells in vivo also decreased the anti-tumor effect of [interleukin-18 + B7-1], suggesting the importance of CD3+ T cells. Collectively, combination with interleukin-18 and B7-1 expression has synergistic anti-tumor effects against B16 murine melanoma.

AB - Interleukin-18 has been described recently as a cytokine secreted primarily by Kupffer cells. Furthermore, it has been shown that it has significant anti-tumor effects, which are mediated by T cells and natural killer cells, in a manner similar to interleukin-12. Here, we report the evaluation of the effects of the systemic administration of interleukin-18 in combination with B7-1 (CD80) expressed on tumor cells [interleukin-18 + B7-1] on the growth of murine B16 melanoma in vivo. After the subcutaneous inoculation of B16 melanoma, B16 tumors grew progressively in immunocompetent syngeneic C57BL/6 mice. Mice treated with either interleukin-18 or immunized with B7-1-transduced B16 did not demonstrate significant anti-tumor effect. The combination of the two treatments, however, resulted in dramatic suppression of melanoma formation, tumor growth, and a significant improvement in survival. Inhibitory effects of [interleukin-18 + B7-1] on lung metastasis in mice were also detected. Additionally, mice treated with [interleukin-18 + B7-1] showed an increase of natural killer cytotoxicity and interferon-γ production in vivo. Unlike [interleukin-18 + B7-1], [interleukin-12 + B7-1] did not have a strong antitumor effect against B16 melanoma. Histologic characterization after the [interleukin-18 + B7-1] treatment confirmed the infiltration of natural killer cells into the tumor, suggesting that natural killer cells may be involved in the [interleukin-18 + B7-1]-induced anti-tumor effect. This finding was confirmed by showing that depletion of NK1.1+ cells before immunization inhibits the [interleukin-18 + B7-1]-induced anti-tumor effect. Depletion of CD3+ cells in vivo also decreased the anti-tumor effect of [interleukin-18 + B7-1], suggesting the importance of CD3+ T cells. Collectively, combination with interleukin-18 and B7-1 expression has synergistic anti-tumor effects against B16 murine melanoma.

KW - Anti-tumor effect

KW - B7-1

KW - Immunotherapy

KW - Interleukin-18

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=0001543990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001543990&partnerID=8YFLogxK

U2 - 10.1038/sj.jid.5600685

DO - 10.1038/sj.jid.5600685

M3 - Article

C2 - 10771473

AN - SCOPUS:0001543990

VL - 114

SP - 928

EP - 934

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 5

ER -